Zanubrutinib is preferred over ibrutinib for CLL due to its improved safety profile and lower cardiovascular risks, especially in patients with comorbidities. Dr. Narang emphasizes the importance of ...
In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results